GlassScriptPhysician profile
Steven Mc Lum
NPI 1790874972
$6,759.50
in general payments reported to CMS, 2019-2025
23 companies · $304 in 2025
The $304 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,791 · 2020: $1,328 · 2021: $1,603 · 2022: $985 · 2023: $587 · 2024: $161 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,032 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,032.34 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,472.51 | 2019-2025 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $1,357.57 | 2019-2023 | |
| Amgen INC. | $869.70 | 2019-2025 | Evenity, Prolia, Tepezza |
| Sanofi-Aventis U.S. LLC | $505.94 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $438.30 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $320.23 | 2019-2022 | |
| Dexcom, INC. | $308.30 | 2022-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $251.49 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $238.02 | 2019-2025 | Breztri |
| Lilly USA, LLC | $186.22 | 2020-2023 | Trulicity, Mounjaro |
| Astellas Pharma US INC | $158.50 | 2019-2023 | Myrbetriq |
| Kowa Pharmaceuticals America, INC. | $147.28 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $125.00 | 2019 | |
| Abbott Laboratories | $91.43 | 2022-2023 | Freestyle Libre 3 |
| Abbvie INC. | $75.32 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $54.19 | 2020-2022 | |
| Mannkind Corporation | $39.94 | 2025 | |
| Pfizer INC. | $31.25 | 2020 | |
| Radius Health, INC. | $22.93 | 2020 | |
| Horizon Therapeutics Plc | $20.81 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.62 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $13.99 | 2019 | |
| Allergan, INC. | $10.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Lum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.